New Opportunities in Non-Preservative Glaucoma Therapy
Most of the medicines used for the treatment of glaucoma include a preservative in various concentrations. With long-term topical therapy, patients with glaucoma may develop dry eye syndrome (DES). The severity of symptoms depends on the number of drugs used and the presence of a preservative in the...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ophthalmology Publishing Group
2021-07-01
|
| Series: | Oftalʹmologiâ |
| Subjects: | |
| Online Access: | https://www.ophthalmojournal.com/opht/article/view/1542 |
| _version_ | 1797875455799328768 |
|---|---|
| author | A. A. Antonov I. V. Kozlova A. A. Vitkov |
| author_facet | A. A. Antonov I. V. Kozlova A. A. Vitkov |
| author_sort | A. A. Antonov |
| collection | DOAJ |
| description | Most of the medicines used for the treatment of glaucoma include a preservative in various concentrations. With long-term topical therapy, patients with glaucoma may develop dry eye syndrome (DES). The severity of symptoms depends on the number of drugs used and the presence of a preservative in them. Against the background of DES progression, compliance to glaucoma therapy may decrease, and, consequently, the effectiveness of the treatment may decrease. Currently, new non-preservative hypotensive drugs containing brimonidine, as well as a fixed combination (FC) of dorzolamide and timolol, are available on the market.Purpose: to compare assessment of the hypotensive effect and tolerability of preservative-free drugs FC Dorzolamid 20 mg/ml, Timolol 5 mg/ml (Dortmol Antiglau ECO) and Brimonidine 2 mg/ml (Brim Antiglau ECO) when switching from similar drugs containing a preservative in patients with compensated glaucoma.Patients and methods. In this prospective clinical study, 60 patients (60 eyes) with compensated primary open-angle glaucoma on combined topical therapy were examined. In group 1 (30 patients, 30 eyes), the combinations of dorzolamide / timolol or brinzolamide / timolol were switched with the non-preservative Dortmol Antiglau ECO. In group 2 (30 patients, 30 eyes), the brimonidine as part of the medication regimen were replaced with the non-preservative Brim Antiglau ECO. The level of corneal-compensated IOP was assessed before the switch in therapy and after 1 month. Subjective feelings and objective signs of the treatment’s use were monitored during examination and using a questionnaire, which was compiled to study the tolerance of therapy.Results. Switching to a preservative-free combination of dorzolamide and timolol resulted in a reduction in complaints of irritation, lacrimation, and foreign body sensation. The efficiency control did not reveal a significant change (p > 0.05) in the cornealcompensated intraocular pressure (IOPcc). When transferred to the Brim Antiglau ECO as part of the local hypotensive treatment, intraocular pressure decreased significantly (p < 0.05). The average total score characterizing drug intolerance, when evaluated by the patient, decreased by 2.4 times, by the attending physician-by 1.9 times. The degree of conjunctival hyperemia on the MacMonnies photographic scale decreased in both groups.Conclusion. Preservative-free drugs can be recommended for most patients with glaucoma as a starting treatment and as a replacement for current therapy. |
| first_indexed | 2024-04-10T01:46:46Z |
| format | Article |
| id | doaj.art-733cd38993e94ee28a2b689d30b3ac22 |
| institution | Directory Open Access Journal |
| issn | 1816-5095 2500-0845 |
| language | Russian |
| last_indexed | 2024-04-10T01:46:46Z |
| publishDate | 2021-07-01 |
| publisher | Ophthalmology Publishing Group |
| record_format | Article |
| series | Oftalʹmologiâ |
| spelling | doaj.art-733cd38993e94ee28a2b689d30b3ac222023-03-13T09:08:41ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452021-07-0118226026510.18008/1816-5095-2021-2-260-265755New Opportunities in Non-Preservative Glaucoma TherapyA. A. Antonov0I. V. Kozlova1A. A. Vitkov2ФГБНУ «Научно-исследовательский институт глазных болезней»ФГБНУ «Научно-исследовательский институт глазных болезней»ФГБНУ «Научно-исследовательский институт глазных болезней»Most of the medicines used for the treatment of glaucoma include a preservative in various concentrations. With long-term topical therapy, patients with glaucoma may develop dry eye syndrome (DES). The severity of symptoms depends on the number of drugs used and the presence of a preservative in them. Against the background of DES progression, compliance to glaucoma therapy may decrease, and, consequently, the effectiveness of the treatment may decrease. Currently, new non-preservative hypotensive drugs containing brimonidine, as well as a fixed combination (FC) of dorzolamide and timolol, are available on the market.Purpose: to compare assessment of the hypotensive effect and tolerability of preservative-free drugs FC Dorzolamid 20 mg/ml, Timolol 5 mg/ml (Dortmol Antiglau ECO) and Brimonidine 2 mg/ml (Brim Antiglau ECO) when switching from similar drugs containing a preservative in patients with compensated glaucoma.Patients and methods. In this prospective clinical study, 60 patients (60 eyes) with compensated primary open-angle glaucoma on combined topical therapy were examined. In group 1 (30 patients, 30 eyes), the combinations of dorzolamide / timolol or brinzolamide / timolol were switched with the non-preservative Dortmol Antiglau ECO. In group 2 (30 patients, 30 eyes), the brimonidine as part of the medication regimen were replaced with the non-preservative Brim Antiglau ECO. The level of corneal-compensated IOP was assessed before the switch in therapy and after 1 month. Subjective feelings and objective signs of the treatment’s use were monitored during examination and using a questionnaire, which was compiled to study the tolerance of therapy.Results. Switching to a preservative-free combination of dorzolamide and timolol resulted in a reduction in complaints of irritation, lacrimation, and foreign body sensation. The efficiency control did not reveal a significant change (p > 0.05) in the cornealcompensated intraocular pressure (IOPcc). When transferred to the Brim Antiglau ECO as part of the local hypotensive treatment, intraocular pressure decreased significantly (p < 0.05). The average total score characterizing drug intolerance, when evaluated by the patient, decreased by 2.4 times, by the attending physician-by 1.9 times. The degree of conjunctival hyperemia on the MacMonnies photographic scale decreased in both groups.Conclusion. Preservative-free drugs can be recommended for most patients with glaucoma as a starting treatment and as a replacement for current therapy.https://www.ophthalmojournal.com/opht/article/view/1542глаукомагипотензивная терапиябесконсервантная терапияглазная поверхностьдорзоламидтимололбримонидин |
| spellingShingle | A. A. Antonov I. V. Kozlova A. A. Vitkov New Opportunities in Non-Preservative Glaucoma Therapy Oftalʹmologiâ глаукома гипотензивная терапия бесконсервантная терапия глазная поверхность дорзоламид тимолол бримонидин |
| title | New Opportunities in Non-Preservative Glaucoma Therapy |
| title_full | New Opportunities in Non-Preservative Glaucoma Therapy |
| title_fullStr | New Opportunities in Non-Preservative Glaucoma Therapy |
| title_full_unstemmed | New Opportunities in Non-Preservative Glaucoma Therapy |
| title_short | New Opportunities in Non-Preservative Glaucoma Therapy |
| title_sort | new opportunities in non preservative glaucoma therapy |
| topic | глаукома гипотензивная терапия бесконсервантная терапия глазная поверхность дорзоламид тимолол бримонидин |
| url | https://www.ophthalmojournal.com/opht/article/view/1542 |
| work_keys_str_mv | AT aaantonov newopportunitiesinnonpreservativeglaucomatherapy AT ivkozlova newopportunitiesinnonpreservativeglaucomatherapy AT aavitkov newopportunitiesinnonpreservativeglaucomatherapy |